Shoji, T.; Takatori, E.; Nagasawa, T.; Kagabu, M.; Baba, T.; Shigeto, T.; Matsumura, Y.; Shimizu, D.; Terada, Y.; Seino, M.;
et al. Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study). Cancers 2024, 16, 3801.
https://doi.org/10.3390/cancers16223801
AMA Style
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, Matsumura Y, Shimizu D, Terada Y, Seino M,
et al. Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study). Cancers. 2024; 16(22):3801.
https://doi.org/10.3390/cancers16223801
Chicago/Turabian Style
Shoji, Tadahiro, Eriko Takatori, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba, Tatsuhiko Shigeto, Yukiko Matsumura, Dai Shimizu, Yukihiro Terada, Manabu Seino,
and et al. 2024. "Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study)" Cancers 16, no. 22: 3801.
https://doi.org/10.3390/cancers16223801
APA Style
Shoji, T., Takatori, E., Nagasawa, T., Kagabu, M., Baba, T., Shigeto, T., Matsumura, Y., Shimizu, D., Terada, Y., Seino, M., Ohta, T., Nagase, S., Shigeta, S., Tokunaga, H., Shimada, M., Kaiho-Sakuma, M., Furukawa, S., Soeda, S., Watanabe, T.,
... Yokoyama, Y.
(2024). Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study). Cancers, 16(22), 3801.
https://doi.org/10.3390/cancers16223801
